- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.11. | Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod | ||
| 14.11. | Survey reveals 'cardiology deserts' at heart of Amgen-backed campaign | ||
| 14.11. | Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid | ||
| 14.11. | Biopharma industry gathers momentum in Q3 | ||
| 14.11. | Fierce Pharma Asia-Pfizer's PD-1xVEGF trials; ivonescimab's 1st survival win; Lilly's deal spree | ||
| 13.11. | Bavarian Nordic board chair exits in aftermath of failed private equity takeover | ||
| 13.11. | Lilly, Novo shoot down claims of DTC obesity drug partnership with Mangoceuticals | ||
| 13.11. | Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval | ||
| 13.11. | Boryung breaks ground on penicillin plant expansion in South Korea | ||
| 13.11. | Gilead hails phase 3 victory for single-tablet combo of bictegravir and lenacapavir, preps filings | ||
| 12.11. | Recall roundup: Fresenius, Sun and Teva among drugmakers pulling products in recent weeks | ||
| 12.11. | Lundbeck, Otsuka back survey uncovering 'blind spot' around Alzheimer's agitation | ||
| 12.11. | As pharma sales stagnate, Bayer exec stands firm behind newer meds and latest launch Lynkuet | ||
| 12.11. | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T | ||
| 11.11. | Lilly stitches 'Queer Eye' star Tan France into Zepbound campaign to unravel obesity stigma | ||
| 11.11. | Bayer celebrates scientific breakthroughs, battles misinformation in US corporate campaign | ||
| 11.11. | With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health | ||
| 10.11. | Catalent cuts 77 more jobs in Maryland as gene therapy resizing rolls on | ||
| 10.11. | Sanofi touts mission to 'chase the miracles of science' in new corporate campaign | ||
| 10.11. | Novo forges partnership with Emcure to expand Wegovy access in India | ||
| 10.11. | Pfizer's challenge of BridgeBio ads referred to federal agencies | ||
| 07.11. | J&J brings 'invisible illness' IBD out of the shadows with report supporting the power of patient community | ||
| 07.11. | Regeneron, AstraZeneca eye green lights after separate trial wins for Dupixent, Fasenra in inflammatory conditions | ||
| 07.11. | TV ad spending skyrocketed to new heights in October, led by record outlay for J&J's Tremfya | ||
| 07.11. | Gilead's Trodelvy stumbles in first-line breast cancer trial, adding to shaky clinical track record |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .